Articles tagged with: Meeting Update
News»
Interim results of a Phase 3 trial show no statistically significant differences in relapse and overall survival rates between multiple myeloma patients who received a donor stem cell transplant as their second transplant compared to patients receiving two sequential transplants with their own stem cells.
Patients who received a donor transplant had an increased risk of death and other serious side effects, which outweighed the therapeutic benefits of the procedure.
The results of the trial were presented yesterday by Dr. Amrita Krishnan from the City of Hope Cancer Center in Duarte, California, at the American Society of …
News»
Yesterday was the second full day of the 2010 American Society of Hematology annual meeting in Orlando. It was a particularly busy day in terms of material related to multiple myeloma, with numerous oral presentations during the day and an extensive poster session in the early evening.
One of the first presentations of the day was actually a press conference held to review the results of a Phase 3 study comparing the efficacy and safety of two different stem cell transplant regimens for multiple myeloma (abstract).
In one arm of this …
News»
Carfilzomib continues to show promising results in multiple myeloma according to four studies presented in a poster session yesterday at the 2010 American Society of Hematology annual meeting in Orlando.
Carfilzomib (Kyprolis), developed by Onyx Pharmaceuticals, is a new drug that is currently being investigated as a potential treatment for multiple myeloma. It belongs to the same class of drugs as Velcade (bortezomib). However it works slightly differently by binding to different proteins than Velcade.
Recent research has indicated that carfilzomib is effective for patients with relapsed or refractory (resistant) myeloma who …
News»
The American Society of Hematology meeting swung into full gear yesterday. The day was full of invited talks and a poster session.
The morning kicked off with an education session in which attendees could learn about several myeloma-related topics.
The first presentation was by Dr. Ola Landgren from the National Cancer Institute and National Institutes of Health in Bethesda, Maryland. Dr. Landgren spoke about monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, precursor diseases of multiple myeloma.
A study published by Dr. Landgren last year showed that all multiple myeloma patients have …
News»
The 52nd annual meeting of the American Society of Hematology (ASH) will kick off this Saturday, December 4, in Orlando. Experts from around the world will present the latest research about various blood diseases, including multiple myeloma, and The Myeloma Beacon will provide comprehensive coverage of the meeting as it happens.
“The Myeloma Beacon will be a one-stop source for myeloma-related news from the ASH meeting,” said Boris Simkovich, publisher of The Myeloma Beacon.
Similar to the Beacon’s coverage of the American Society of Clinical Oncology meeting in June, The Beacon will …
News»
The 52nd annual meeting of the American Society of Hematology will take place Saturday, December 4, through Tuesday, December 7.
During the four-day meeting, clinical specialists from all over the world will discuss current research regarding the diagnosis and treatment of various blood diseases, including multiple myeloma. Over 20,000 people are expected to attend the event.
The American Society of Hematology (ASH) meeting will include many presentations and posters focused on myeloma. The ASH website currently lists about 350 myeloma-related abstracts that will be presented in various poster sessions and oral presentations …
NewsFlash »
Updated Data On Revlimid-Based Therapy Versus Stem Cell Transplantation For Myeloma Presented At ESMO Meeting – Intermediate results for a study comparing the efficacy of Revlimid (lenalidomide)-based therapy with the efficacy of stem cell transplantation were presented at the European Society for Medical Oncology (ESMO) meeting earlier this month. Half of the patients were treated with melphalan (Alkeran), prednisone, and Revlimid, known as MPR. The other half of patients were treated with high-dose melphalan followed by stem cell transplantation. Initial results presented at the American Society of Clinical Oncology Annual Meeting this summer showed that a complete response was achieved by 13 percent of patients receiving MPR and 16 percent of patients receiving a transplant (see related Beacon news). The updated results at ESMO showed complete response rates of 14 percent and 25 percent, respectively. Although the complete response rate for stem cell transplantation is higher than the rate for Revlimid-based therapy, the rates for the two treatment groups remain similar. For more information, see the ESMO website.
Multiple Myeloma Educational Program – An educational program for multiple myeloma patients will be held on November 6 in Conshohocken, PA. Dr. Patricia Kropf from Temple Cancer Center will talk about treatment options for myeloma patients as well as answer attendee’s questions. A multiple myeloma patient will also speak about his experiences. Registration will begin at 9:30 a.m., and the program will start at 10 a.m. at the Philadelphia Marriott West. The event is sponsored by Millennium. For more information, see the Beacon event description or call 1-866-508-6181.
Southwest Multiple Myeloma Symposium – A free workshop for multiple myeloma patients and their families will be held at Arizona State University on November 6. Dr. Joseph Mikhael from the Mayo Clinic will lead the workshop. He and other specialists will speak about multiple myeloma, treatment options, and side effects. There will also be a question and answer session at the end of the workshop. Registration will begin at 8 a.m., and the program will run from 8:30 a.m. until 3 p.m. with lunch included. For more information, see the International Myeloma Foundation website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.